Search Results
Feb 23, 2026, 09:00 ET Complete Genomics Enters Definitive Agreement to Be Acquired by Swiss Rockets AG
Rockets is an innovator in targeted cancer therapies and next-generation vaccines. Complete Genomics, with its long history in next-generation sequencing (NGS) and novel chemistries and technology, complements and enables the long-term vision of Swiss Rockets by expanding access to precision medicine and wellness
More news about: Complete Genomics
Feb 20, 2026, 10:00 ET New England Biolabs® to present latest updates in Next Generation Sequencing Sample Preparation at 2026 AGBT Meeting
IPSWICH, Mass., Feb. 20, 2026 /PRNewswire/ -- New England Biolabs (NEB®) will be presenting exciting updates in NGS library preparation technology at this year's Advances in Genome Biology and Technology (AGBT) Meeting. As a Bronze Meeting Sponsor, NEB will be introducing
More news about: New England Biolabs, Inc.
Feb 18, 2026, 11:40 ET Precision Medicine Research and Development Platform Market Forecast 2031: Genomics, Proteomics, and AI Accelerate Industry Expansion | Valuates Reports
Cancer NGS Testing Platform Market was valued at USD 527 Million in the year 2024 and is projected to reach a revised size of USD 1381 Million by 2031,
More news about: Valuates Reports
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
Miscarriage Testing Market by Technology (Chromosomal Microarray Analysis (CMA), Next-Generation Sequencing (NGS), Conventional Karyotyping, Fluorescence in Situ Hybridization), Application (Recurrent Pregnancy Loss (RPL), First-Time Sporadic, Stillbirth Analysis,
More news about: Persistence Market Research Pvt. Ltd.
Feb 17, 2026, 10:01 ET Scar Treatment Market to Reach US$ 49.2 Bn by 2033 Expands Amid Rising Aesthetic Demand and Technological Innovation - Persistence Market Research
Miscarriage Testing Market by Technology (Chromosomal Microarray Analysis (CMA), Next-Generation Sequencing (NGS), Conventional Karyotyping, Fluorescence in Situ Hybridization), Application (Recurrent Pregnancy Loss (RPL), First-Time Sporadic, Stillbirth Analysis,
More news about: Persistence Market Research Pvt. Ltd.
Feb 16, 2026, 10:46 ET Genotyping Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research
toward proactive healthcare strategies.Technological advancements in genotyping also fosters the rise in demand. Next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray technologies have made genotyping faster, accurate, and affordable. These improvements reduce testing
More news about: Allied Market Research
Feb 12, 2026, 15:36 ET National Genealogical Society Welcomes Major General (Retired) Garrett Yee as Honorary Chairman of Veteran Bounty Land Records Capital Campaign
SILVER SPRING, Md., Feb. 10, 2026 /PRNewswire/ -- The National Genealogical Society (NGS) is proud to announce the appointment of Major General (Retired) Garrett S. Yee as Honorary Chairman of the Veteran Bounty Land Records (VBLR) capital
More news about: National Genealogical Society
Feb 11, 2026, 10:50 ET Genomics Market to Reach $97.1 Billion by 2033 Globally, at 11.5% CAGR: Allied Market Research
in 2023By technology, the sequencing segment accounted for the highest revenue in the genomics market in 2023. Next-generation sequencing (NGS) is widely adopted due to its high accuracy, scalability, and declining cost per genome. It plays a critical role in oncology profiling, rare disease
More news about: Allied Market Research
Feb 06, 2026, 12:09 ET New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally
Genomics, Eppendorf, Hamilton Company, Revvity, and SPT Labtech to support customer implementation of NEBNext® reagents for next-generation sequencing (NGS) library preparation.
More news about: New England Biolabs, Inc.
Feb 05, 2026, 16:06 ET Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Jacob Thaysen, Chief Executive Officer of Illumina. "Momentum built in the second half of the year – especially in clinical markets, where adoption of NGS-based testing is expanding – reinforces our confidence as we enter 2026."Fourth quarter results
More news about: Illumina, Inc.
Feb 05, 2026, 08:15 ET Palo Alto Networks NextWave Program Accelerates Partner Profitability and AI-Driven Security Outcomes
benefits:Enhancing Partner Margins: Streamlined rebates focus on Next-Generation Firewalls (NGFW), Next-Generation Security (NGS) and platformization to reward technical expertise and maximize profitability.Accelerating Deal Velocity: Enhanced Configure, Price,
More news about: Palo Alto Networks, Inc.
Feb 02, 2026, 08:52 ET Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
specimens instead of bone marrow aspirates. In addition, the test can be used in situations where a baseline aspirate sample is not available, unlike NGS methods, which require a pre-treatment baseline sample to provide a reference for ongoing monitoring. The test also features five-day specimen stability,
More news about: Quest Diagnostics
Jan 30, 2026, 09:05 ET Illumina completes acquisition of SomaLogic
bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN
More news about: Illumina, Inc.
Jan 29, 2026, 09:25 ET AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
insights don't have to be," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Paige Predict overcomes one of the biggest barriers in NGS by delivering actionable information to inform critical testing decisions for patient care when sequencing isn't feasible."Paige Predict analyzes
More news about: Equity Insider
Jan 28, 2026, 16:30 ET ePlus Announces Third Quarter and Nine Month Fiscal Year 2026 Earnings Release Date and Conference Call
HERNDON, Va., Jan. 28, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jan 22, 2026, 10:30 ET Next-Generation Sequencing Market worth $29.53 billion by 2030 | MarketsandMarkets™
government funding for sequencing projects, rising applications of NGS in chronic disorders, and growing applications of NGS in clinical diagnostics.Steady advances in bioinformatics and data analytics are key drivers of the NGS market's growth. These tools facilitate the processing of sequencing
More news about: MarketsandMarkets
Jan 21, 2026, 08:00 ET Pangea Laboratory and Gene Solutions Establish Strategic Collaboration to Advance Cancer Diagnostics in the United States
Leveraging multi-omics, Next-Generation Sequencing (NGS), and AI, the company offers a portfolio including multi-cancer early detection (SPOT-MAS) and comprehensive tumor profiling with ctDNA monitoring (K-TRACK, K-4CARE). Gene Solutions operates CAP-accredited NGS laboratories and has delivered Three million
More news about: Pangea Laboratory
Jan 21, 2026, 06:44 ET Veterinary Diagnostics Market to Expand at 10.75% CAGR by 2035 | Discover Strategic Opportunities with Vantage Market Research
https://www.vantagemarketresearch.com/industry-report/single-cell-analysis-market-1295NGS informatics Market is valued at USD 7.21 Billion in 2024 and is projected to reach a value of USD 25.43 Billion by 2035 at a CAGR (Compound Annual Growth
More news about: Vantage Market Research
Jan 20, 2026, 10:30 ET Nucleic Acid Isolation and Purification Market worth $10.99 billion by 2030 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229978287 The market for nucleic acid isolation and purification (NAIP) is expanding consistently with the rapid adoption of NGS in research and clinical labs. NAIP consumption is increasing significantly in high-impact settings such as oncology profiling, rare disease testing,
More news about: MarketsandMarkets
Jan 15, 2026, 10:43 ET Cancer Biomarkers Market Surges to USD 45.7 Billion by 2033, Propelled by 8.6% CAGR - Verified Market Reports®
CompaniesBy TechnologyImmunoassaysPolymerase Chain Reaction (PCR)Next-Generation Sequencing (NGS)Mass SpectrometryCancer Biomarkers Market, By GeographyNorth America
More news about: Verified Market Reports
Jan 15, 2026, 07:00 ET BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence
studies for MRD assays. The protocols can be adapted and applied to any tumor-informed MRD assay, irrespective of technology—next-generation sequencing (NGS) or digital PCR (dPCR), panel design algorithm, or workflow component."These protocols reflect a deep collaborative effort and a shared commitment
More news about: Blood Profiling Atlas in Cancer (BLOODPAC) Consortium
Jan 15, 2026, 07:00 ET BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence
studies for MRD assays. The protocols can be adapted and applied to any tumor-informed MRD assay, irrespective of technology—next-generation sequencing (NGS) or digital PCR (dPCR), panel design algorithm, or workflow component."These protocols reflect a deep collaborative effort and a shared commitment
More news about: Blood Profiling Atlas in Cancer (BLOODPAC) Consortium
Jan 14, 2026, 12:21 ET GenomOncology Partners with OHSU Knight Diagnostics Lab to Accelerate Patient Access to Precision Oncology Clinical Trials
molecular data into actionable intelligence for precision cancer care. The company's AI-enabled reporting solutions deliver embedded decision support for NGS analysis and clinical trial optimization that seamlessly integrates into clinical workflows to better enable accurate decision-making for patient treatment.
More news about: GenomOncology
Jan 14, 2026, 08:00 ET From Path to Progress: Journal of Independent Medicine Launches 2026 With Its Fifth Issue--Entering Year Two of Conflict-Free, Evidence-Based Science
Papoutsis; Thomas Borody; Siba Dolai; Jordan Daniels; Skylar Steinberg; Brad Barrows; Sabine HazanReports 100% concordance between stool NGS and nasopharyngeal RT-PCR in a small cohort, supporting exploratory investigation of fecal SARS-CoV-2 genomic detection and variant characterization. Referendum
More news about: Independent Medical Alliance
Jan 13, 2026, 10:30 ET Predictive Clinical Biomarkers Market worth $14.69 billion by 2030 | MarketsandMarkets™
North America holds the largest share, supported by a dense network of academic centers, cancer institutes, and commercial labs that have widely adopted NGS testing, liquid biopsies, and companion diagnostics. Favorable reimbursement, flagship government initiatives such as the Cancer Moonshot, and strong
More news about: MarketsandMarkets